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Background: Pressure ulcers (PrUs) are ischemic wounds in the skin and underlying tissues caused by
long-standing pressure force over an external bone or cartilaginous surface. PrUs are an important challenge for the
overall health system because can prolong patient hospitalization and reduce quality of life. Moreover, 95% of PrUs
are avoidable, suggesting they are caused by poor quality care assistance. PrUs are also costly, increasing national
costs. For example, they represent about 5% of overall annual health expenses in Spain. Stages I and II PrUs have a
combined prevalence of 65%. According main clinical guidelines, stage II PrUs (PrU-IIs) are usually treated by
applying special dressings (polyurethane or hydrocolloid). However, little scientific evidence regarding their efficacy
has been identified in scientific literature. Our aim is to assess the comparative efficacy of adhesive polyurethane
foam and hydrocolloid dressings in the treatment of PrU-IIs in terms of healed ulcer after 8 weeks of follow-up.
Methods/design: This paper describes the development and evaluation protocol of a randomized clinical trial of
two parallel treatment arms. A total of 820 patients with at least 1 PrU-II will be recruited from primary health care
and home care centers. All patients will receive standardized healing procedures and preventive measures (e.g.
positional changes and pressure-relieving support surfaces), following standardized procedures. The main outcome
will be the percentage of wounds healed after 8 weeks. Secondary outcomes will include cost-effectiveness, as
evaluated by cost per healed ulcer and cost per treated patient and safety evaluated by adverse events.
Discussion: This trial will address the hypothesis that hydrocolloid dressings will heal at least 10% more stage II
PrUs and be more cost-effective than polyurethane foam dressings after 8 weeks.
Trial registration: This trial has been registered with controlled-trials number ISCRCTN57842461 and EudraCT
2012-003945-14.
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Pressure ulcers (PrUs) are ischemic wounds in the skin
and underlying tissues, caused by continuous pressure
from friction or shearing between an external surface
and a bone or cartilaginous surface. Long-standing pres-
sure can reduce capillary blood flow and lead to cell
death, necrosis and broken tissue, or to additional ser-
ious complications, including osteomyelitis, sepsis, con-
tractures, atrophy and psychological disorders [1,2].
These complications may delay mobilization and active
rehabilitation, as well as reducing the ability of patients
to live active and independent lives. PrUs can affect pa-
tients in all health care settings, provoke pain and discom-
fort, decrease quality of life and even increase morbidity
and residence time in healthcare institutions [3,4].
PrUs can also increase direct and indirect healthcare
costs and provide a negative image of healthcare institu-
tions, attributable to deficits in the quality of care, espe-
cially since 95% of PrUs are preventable [1,2]. A national
study has estimated that expenditures related to the onset
of PrU amounts to approximately 5% of the annual health-
care spending in Spain [3,4].
A national prevalence study in 2006 by the GNEAUPP
(Spanish acronym of National Group for the Study and
Advice in Pressure Ulcers and Chronic Wounds) showed
a wide variability in PrUs prevalence among types of insti-
tutions. PrUs have been reported to occur in 3.73% of pa-
tients in domiciliary care, 8.24% of hospitalized patients
and 6.1% of patients in nursing homes. Moreover, 2.1% of
patients with PrUs were aged 0 to 45 years, 6.4% were
aged 46 to 64 years and 87.4% were aged ≥ 65 years [5].
Within each category, PrU incidence was very variable,
ranging from 3-29% in hospitalized patients. Moreover,
PrUs have been observed in 66% of elderly individuals
(risk population) with femur fractures [4-7].
The European Pressure Ulcer Advisory Panel (EPUAP)
has classified PrUs in four stages. Stages I and II are more
frequent, with a combined rate of about 65% [5], although
it differs among studies [8-15]. The EPUAP has defined
stage II PrU (PrU-II) as involving a partial loss in skin
thickness, affecting the epidermis and/or dermis. These
are considered superficial ulcers, clinically manifesting as
abrasions or blisters [8,16].
Prevention is the best treatment for PrU. However,
despite Good Clinical Practice Guidelines (GCP), [17-20]
which report the effectiveness of preventive activities
(adequate nutrition, effective pressure relief, positional
changes, management of incontinence and elimination
of shearing and friction forces), there is little scientific
evidence supporting the efficacy of these measures in
avoiding further problems related to PrUs [1-3].
In contrast, evidence has suggested that PrUs healing
in a moist environment, using special or modern dress-
ings, is more cost effective than traditional cure or dry-to-wet dressings (i.e. dressings that do not maintain a moist
environment) because the former stimulate cell prolifera-
tion. In addition, special dressings act as a barrier against
bacteria, absorb excess wound fluid, reduce pain during
the healing process and create the right conditions (moist
environment) for healing or scarring [1,3,18-20].
The benefits of a moist environment have led to the
development of a flowering variety of synthetic dressings
(special or also called modern dressings). Use of these
dressings depends on the availability of resources, PrU
stage and morphology, and the presence of infection
and/or necrosis [1,3,18-20].
Although GCP guidelines indicate that the special
dressings most frequently used to treat PrU-II are hydro-
colloid and polyurethane foam dressings. To date, how-
ever, systematic reviews and clinical trials have established
a poorly and scarcely evidence of their effectiveness. Al-
though studies have shown benefits of polyurethane dress-
ings, their benefits did not differ significantly from those
of hydrocolloid dressings. In addition, these studies in-
volved patients with various wound types (pressure ulcers
and venous ulcers) and different PrU stages, which may
have affected the results [1,3,18-21].
To overcome these limitations, the present study will
compare two types of dressings in the treatment of PrU-
IIs, both which are recommended and are part of habitual
clinical practice [1,3,19,20]. However, due to the wide vari-
ability in both types of dressing, this study will compare
the adhesive versions of polyurethane and hydrocolloid
dressings.Aim and hypothesis
The main hypothesis of this study is that hydrocolloid
dressings would heal at least 10% more stage II PrUs than
polyurethane foam dressings over 8 weeks of follow-up in
patients with PrU-II.
The aim of the proposed protocol is to compare the
efficacy of adhesive polyurethane foam dressings and ad-
hesive hydrocolloid dressings in the treatment of PrU-II.
The primary objective will be to assess the percentage of
wounds healed after 8 weeks.
Secondary objectives include assessments of:
– improvements in the clinical efficacy of both
dressings, as measured by ulcer area (cm [2]),
exudates, type of tissue (PUSH Scale) and time to
healing (epithelial tissue).
– treatment efficacy, as measured by PrU-II
resolutionwithin study time.
– safety, as determined by adverse events (AE)
attributed to both dressings.
– direct costs of both dressings, as measured by cost
per healed ulcer and cost per treated patient.
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adherence properties, management of the dressing,
comfort, pain during the healing procedure, number
of dressings used and perilesional skin state.
Methods and design
Study design
This will be a multicenter, randomized trial evaluating
and comparing the efficacy of the adhesive polyurethane
foam and hydrocolloid dressings in patients with PrU-II
within the context of habitual prevention measures.
Setting and eligibility criteria
This study will recruit patients who receive primary health
assistance, including patients able to attend the primary
health center or receive health assistance in homes,
nursing-homes and non-acute long term hospitalization
centers. Each patient must present with at least one
PrU-II.
Inclusion criteria
– Age ≥ 18 years.
– Confirmed diagnosis of PrU-II. If a patient has more
than one PrU-II, only the largest diameter ulcer will
be assessed. Other PrU-II will receive the best
treatment elected by the study nurse.
Exclusion criteria
– Stage I, III or IV PrU only.
– Non classifiable PrU.
– Surgical treatment prior to PrU and/or PrU in
previously irradiated areas.
– Participation in another clinical trial within
3 months of study entry.
– Allergy or hypersensitivity to materials in the study
dressings.
– Signs of PrU basal infection (sepsis/bacterial),
cellulitis or osteomyelitis. Patients successfully
treated for infection can be included if the PrU can
be classified as stage II.
– Venous ulcers and/or diabetic feet.
– Type I diabetes.
– Situations of extreme severity and/or agony; e.g.
patients in terminal phase with <3 points on the
Braden scale and/or a life expectancy < 1 month.
Recruitment
Each primary health center or nursing home will have
one or two study nurses to assess eligibility criteria, to
invite potential candidates to participate in the clinical
trial and to carry out all protocol procedures (see section
on Interventions).Potentially eligible patients will be recorded, as well as
reasons for exclusion. All included patients will be given
a patient information sheet and an informed consent form.
Signing of the latter is essential for study inclusion.
If a patient’s clinical condition makes signing of the in-
formed consent form impossible, a relative or guardian
will be responsible for signing; however, those patients
must clearly indicate orally their willingness to participate
in the study.
Any included patient who drops out or is lost during the
clinical trial process will be recorded on the appropriate
form.
Randomization
Participants will be enrolled consecutively by their study
nurse. Each participating center will have a unique
randomization list. This sequential randomization will
be generated in blocks of 12, up to a maximum of 24
recruited patients per center (see Additional file 1:
Figure S1).
Sample size
Assuming that 30% of patients in the polyurethane arm
will show healing of PrU-II at 8 weeks, an alpha risk of
5%, a beta risk of 20% with bilateral contrast and a loss
to follow-up of 15%, 410 individuals will be required in
each treatment arm to detect a ≥10% difference in
healed ulcers [22,23].
Blinding
Due to an inability to mask the appearance of the two
dressings, it will only be possible to mask the final evalu-
ation of PrU.
Interventions
Participants will be randomized to hydrocolloid or polyur-
ethane dressing. All patients will receive a standardized
preventive intervention to reduce pressure and undergo a
PrU healing cure process.
Transversal interventions are designed for pressure
relief and positional changes, favoring an optimal evolu-
tion of stage II PrU (PrU-II). Adequate relief of pressure
forces (shearing or friction) requires changes in position
of bedridden or sitting patients and the use of pressure-
relieving support surfaces (PRSS).
Due to their structure, PRSS can reduce pressure forces,
as well as heat and humidity, increasing patient comfort.
PRSS can cover the entire body or only part of it and can
be found in different sizes and types: mattresses, mats or
cushions. However, it is important to highlight that the
use of PRSS does not mean ignoring other healing proce-
dures, including changes of position, skin care and good
nutritional state. Rather, PRSS use only serves as a com-
plement to the healing process [1].
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duction, study nurses will follow a national GCP rec-
ommendations [1]. Recommendations for frequency of
position changes, as well as specific recommendations
for bedridden and sitting patients, must be taken into
account. Each study nurse or caregiver will be trained
to properly implement the recommendations in the
aforementioned GCP.
Healing cure process addresses the cleansing process
and prevention of infection. Standardization of this
process can be accomplished using recommendations
from the reference GCP. Briefly:
– The wound must be cleaned every time the study
dressing is changed. The first step is to thoroughly
irrigate the wound bed with saline solution to
remove detritus, bacteria and remains of any
previous treatment. A 20 ml syringe of saline
solution adapted with a 0.9 × 25 needle or a 19 mm
catheter. Local antiseptics (e.g. povidone,
chlorhexidine) and skin cleaners should be avoided
because they are cytotoxic to new granulating tissue
and their habitual use can have systemic effects due
to absorption.
– The drying procedure must be also delicate. Rough
material (such as gauzes or sponges) can induce
small traumas on the wound bed, increasing the risk
of infection and interfering with the healing process.
Wound edges should be dry and clean and wound
beds moist. Care should be taken to avoid damaging
healthy tissue during cleansing and drying
procedures.
– Bacterial infection should be prevented. An aseptic
technique should be used if possible, including the
use of clean gloves. Proper healing and debridement
procedures can minimize the risk of infection. If a
patient presents with more than one PrU-II, the
most contaminated one should be left to the end
(i.e. perennial area).
It is important to isolate and remove waste and
contaminated materials in accordance with established
precautions to avoid cross contaminations.
If there is leakage of exudates, lack of adherence or
any situation suggesting loss of study dressing, additional
(secondary) dressings will be used. If this additional sup-
port is inadequate, the study dressing will be changed




Description and features These dressings derive from
polyurethanes and have a hydrophilic structure. Theypresent with a high capacity of autolytic debridement
and absorption of exudates; and keep the wound bed from
drying out, without leaving residuals or decomposing. In
addition, they avoid leakages, stains and odors, keep
periwound skin intact, reduce frictional forces and do
not produce traumas when removed.
Indications These dressings are recommended for all
stages of PrU (with moderate or high exudates). Frequent
monitoring and changes may be necessary when PrUs
become infected.
Contraindications These dressing cannot be combined
with antiseptics (e.g. iodine, chlorhexidine, hypochlorite,
ether or hydrogen peroxide), oxygenated water or sodium
hypochlorite because all of the latter can destroy the
dressing [1,3].
Hydrocolloids
Description and features These dressings are made of
carboxymethylcellulose (CMC) and other hydrocolloids
(elastomers), adherent substances or hydroactive com-
pounds, providing absorption capacity. They are covered
with a polyurethane layer, giving them occlusive or semi
occlusive properties. In addition, they absorb exudates
and necrotic residuals by forming a gel with special color
and odor characteristics, creating a slightly acid environ-
ment with bacteriostatic properties. Moreover, they reduce
friction forces.
Indications These dressings are recommended in non-
infected PrU stages I, II and III; slough ulcers and those
with necrotic tissue (as an autolytic debriding agent) and
granulation phase or epithelialization healing process.
Contraindications These dressings should not be applied
to infected ulcers or those in which bones or tendons
are observed. Ether and aggressive antiseptics should be
avoided when using these dressings [1,3].
Variables
Main outcome variables
The main efficacy outcome of the study is rate of PrU-II
healing or ulcer epithelialization tissue (scored on the
PUSH scales as 0). Two digital photographs will be
taken, one at the beginning and the other at the end of
treatment, and sent to the expert panel committee from
Balearic Islands (GAUPP) for evaluation. This committee
will be blinded to treatments of individual patients.
Secondary outcome variables
Efficacy
Changes in the basal PUSH scale, [24-27] ulcer area (in
cm [2]) at the end of treatment, exudates and tissue type.
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the study or until the PrU-II heals.
Changes in ulcer area in cm [2] will be measured
using ImageJ software [28,29]. Two photographs, taken
at the beginning and end of treatment (8 weeks or
when the wound heals), will be evaluated by members
of the expert panel committee. A <10% difference in
ulcer area measured by two evaluators will be consid-
ered ‘agreement’ and the final measure will be the
average of these measurements. A ≥10% difference in
ulcer area between the two evaluators will be consid-
ered ‘disagreement’ , requiring measurement by a third
investigator, with the final measure being the average
of the two closest measurements. This method has
been used in other studies to evaluate changes in ulcer
area [30].
Cost-effectiveness (partial cost-effectiveness evalu-
ation): cost per proportion of healed ulcers and cost per
treated patient. In both treatment arms, the healing
process registry must reflect information regarding
dressings and material used, including cost per unit
dressing, cost per secondary dressing, additional mater-
ial used for each patient (e.g. saline, gauzes, globes, tub-
ing, syringes), and time spent by each nurse performing
these procedures (mm:ss).
Dressing convenience (patient comfort) [31-33] will
be evaluated by both patients and study nurses using
Likert scales ranging from 1 (worst outcome) to 5 (best
outcome) to assess the following measures:
– Patients: adherence to dressing; pain at dressing
removal; pain during application of dressing;
overall comfort; and time during the healing
process
– Study nurses: adherence to dressing; ease of
applying the dressing; ease of removing the
dressing; absorption by the dressing; perilesional
skin condition, as assessed by erythema;
perilesional skin condition, as assessed by
maceration; and time during the healing process.
Withdrawal criteria
Patients will be removed from the trial if any of the
following conditions are met:
 Infection and/or progression of PrU-II
 Disease progression, requiring discontinuation of the
investigational product treatment regimen or study
requirements.
 An adverse event (AE) that requires
discontinuation of the investigational product or
study procedures.
 Voluntary withdrawal
 Loss of follow-upProtocol deviations will be registered. In case of a ser-
ious protocol deviation, the research team will assess the
possibility of withdrawing the patient from the study.
Study discontinuations must be registered in the CRF,
and, where possible, tests and procedures usually per-
formed at the final visit (visit 8 or end of study) should
be carried out. Patients who withdraw due to AEs must
be followed until the end of the study (8 weeks), and if
necessary until AE resolution.
Work plan
Before the trial begins, the study protocol will be pre-
sented to all research team members in a special meeting.
A training session lasting 3–4 h will include a review of
the inclusion and exclusion criteria, provide instructions
regarding interventions and the procedure to use to fill
out the Case Report Form (CRD), as well as assessing the
ethical requirements for the trial. The protocol to be used
to collect information from each patient at each study visit
will include (see Additional file 2: Table S1):
 Selection visit (screening)
– Assessment of inclusion/exclusion criteria
– Signing informed consent form
 Visit 1 (baseline). If patients agree to participate in
the study at the selection visit, all scheduled activities
for visit 1 can be performed at the selection visit. If
patients require time to think about participating,
these scheduled activities will be performed at visit 1.
– Randomization process
– Collection of demographic data, including date of
birth, sex, and place of usual care
– Risk factors for PrU, using the Braden scale
– PUSH Scale registry, including area of each lesion
(width × length), volume of exudates and tissue
type
– PrU photographic registry
– Healing process registry: reason to change
dressing, time treated by the nurse, materials
used
– Training about transverse care (positional
changing and pressure reduction)
– Recording of concomitant medications
– Recording of adverse events
 From Visit 2 to Visit 7 (Follow-up)
– Assessment of inclusion/exclusion criteria
– Assessment of transverse interventions, from
each patient’s diary and nursing files
– PUSH Scale registry, including area of each lesion
(width × length), volume of exudates and tissue
type
– Healing process registry: reason to change
dressing, time treated by the nurse, materials
used
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– Recording of adverse events
 Between visits. The study protocol includes 8 study
visits. If patients require a change of dressing,
between visits,it must be recorded in the CRF, with
the following information collected.
– Date of dressing change
– Reason for dressing change (exudates, lack of
adherence, other reasons)
– Time treated by the nurse (mm:ss)
– Materials used
 Visit 8 or End of study
– PUSH Scale registry: diameter of each lesion
(width × length), volume of exudates and tissue
type.
– Completion of the dressing scale comfort
instrument by patients and study nurses
– Braden scale
– PrU photographic registry
– Recording of concomitant medications
– Recording of adverse events
This study will last 8 weeks (8 visits) or until the ulcer
heals, whichever comes first. The protocol for Visit 8
can include 3 different situations:
1. PrU-II heals before week 8 (visit 8). If complete
healing is observed at an earlier visit, the nurse will
perform the activities described for that Visit plus
those described for Visit 8.
2. PrU-II does not heal by week 8 (visit 8). The nurse
will perform all the activities described for Visit 8.
3. The patient presents some withdrawal criteria before
week 8 (Visit 8). The nurse will perform all the
activities described for the earlier visit, as well as
those described for Visit 8.
Statistical analysis
Intention to treat analysis (ITT)
All statistical calculations will be based on ITT analysis,
including all patients randomized, whether treated or
not, and including all patients who have withdrawn pre-
maturely. This approach reduces any bias that may occur
when participants not receiving assigned treatments are
excluded from analysis. All tests will be two-sided and α-
values of 0.05 will be considered statistically significant.
Descriptive analysis of the patients
The trial involves a descriptive analysis of the baseline
characteristics of patients in both treatment arms. Quanti-
tative variables will be reported in measures of central ten-
dency (mean or median) and the corresponding standard
deviation or interquartile range. Qualitative variables will
be reported as proportions.Baseline comparisons
Baseline qualitative variables in the two treatment arms
will be compared using chi square tests (χ2), and quantita-
tive variables using Student’s t-tests. Non-parametric tests
will be used when distributions are not normal.
Comparative analysis
In a bivariate analysis, a χ2 test will be used to assess
whether the percentage of healed PrU-IIs differs signifi-
cantly in the two treatment arms. Mean changes in PrU
size will be compared using Student’s t-tests for normal
distributions or the Mann-Whitney U test against the
usual null hypothesis (non-normal distributions): (initial
area-final area)*100/initial area). In addition, 95% confi-
dence intervals will be calculated to assess the clinical
significance of treatment.
A logistic regression model adjusted for potential con-
founders will be performed when patients are not equally
distributed in both treatment arms. Relative and absolute
risk reduction and number needed to treat, defined as the
estimated number of ulcers needed to be treated with the
chosen dressing for one additional ulcer to be healed will
be estimated, along with their corresponding 95% CIs.
Time to healing in the two treatment arms will be calcu-
lated by the Kaplan-Meier method and compared using
the log-rank test. A Cox regression model of proportional
risks will be used when the models require adjustment for
any statistically significant baseline variable.
Finally, a partial economic evaluation will be performed,
including direct costs such as number of dressings used
per patient, additional dressings used, materials used,
labor cost per cured ulcer and further treatment cost. The
overall differences in mean costs and effects between
treatments will be calculated using Student’s t-tests.
Ethics
The trial has been approved by the Balearic Island Ethic
Committee. It will be performed by qualified nurses.
The rights and welfare of patients will be respected
throughout the trial. All involved patients will be in-
formed, verbally and in writing, of the trial objectives, risks
and possible benefits. Signed informed consent form will
be required from each patient. The trial will respect and
follow the standards of good clinical practice enshrined in
the Declaration of Helsinki [34,35].
Discussion
PrUs are an important health problem, not only due to
their high incidence and prevalence but to their effects
on health and quality of life. Of these lesions, about 40%
have been categorized as stage II [36,37].
PrU-II treatment consists mainly of the application of
polyurethane and hydrocolloid dressings, which are rec-
ommended and part of habitual clinical practice. However,
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of dressings.
Among available data, highlights a recent systematic re-
view evaluating the effectiveness of modern dressings in
the treatment of venous ulcers [21] found that hydrocol-
loid dressings were the most common type, evaluated in
27 of 45 (60%) clinical trials (CTs). Most of these CTs
compared hydrocolloid dressing with other types of dress-
ings or compared different types of hydrocolloid dressings.
The review included a meta-analysis of four CTs, involv-
ing 311 patients, [38-41] comparing the effectiveness of
hydrocolloid and polyurethane foam dressings for venous
ulcers, with the primary outcome being the total number of
healed ulcers in 8–12 weeks. However, that analysis found
no statistically significant difference in the healing rates
with dressings (pooled relative risk (RR) 0.98; 95% CI, 0079
to 1.22).
Similarly, another meta-analysis of three CTs [23,42,43]
comparing the effectiveness of hydrocolloid dressings with
preparations of polyurethane foams in treating 129 pa-
tients with PrUs [20], found no significant between group
difference (RR, 0.82; 95% CI, 0.57 to 1.17).
Most previous studies comparing polyurethane and
hydrocolloid dressings have methodological shortcomings,
reducing the value of their results and conclusions. These
included small sample sizes, resulting in low statistical
power, as well as a lack of patient follow up, absence of
ITT analysis, different outcome measures, and the inclu-
sion of various wound types and different PrU stages.
Furthermore, among the many types of PrU treatments
and dressings currently in use are silicone hydrogels,
hydrocellular polyurethanes and polyurethane foams,
hydropolymeric silicone and foams, hydrocolloids, and
antimicrobial bioactive collagen (collagenase). However
the use of most is based on little scientific evidence [3].
However, scientific evidence is required to optimize the
treatment of PrU-II, and pressure ulcers in general.
This study has been designed to avoid the methodological
problems encountered in other studies and to provide bet-
ter evidence for optimal PrU-II treatment. Our protocol in-
cludes training sessions for nursing staff involved in the
conduct of the trial, and standardizing data collection.
Identification of optimal dressings can improve patient
quality of life and decrease treatment costs. It won’t be
able to succeed unless we don’t stop and try to shed light
on this health problem with the resources which are at
our disposal and are recommended in the main GCP
guidelines with little evidence about them.Additional files
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